Informações:
Falhas:
ID
18940
Descrição
Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01689714
Link
https://clinicaltrials.gov/show/NCT01689714
Palavras-chave
Versões (2)
- 18/11/2016 18/11/2016 -
- 25/11/2016 25/11/2016 -
Transferido a
25 de novembro de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Ovarian Carcinoma NCT01689714
Eligibility Ovarian Carcinoma NCT01689714
- StudyEvent: Eligibility
Similar models
Eligibility Ovarian Carcinoma NCT01689714
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Clinical Trial Eligibility Criteria Requirement
Item
subjects must meet the following eligibility requirements to be enrolled in the study.
boolean
C1516637 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C1514873 (UMLS CUI [1,2])
Age
Item
1. subject must be 18 years of age or older.
boolean
C0001779 (UMLS CUI [1])
Ovarian Carcinoma | Recurrent Endometrial Cancer | Lesion size | Lesion Quantity | Ultrasonography | Magnetic Resonance Imaging | X-Ray Computed Tomography
Item
2. subject must have known or strongly suspected ovarian carcinoma or recurrent endometrial carcinoma with at least one identifiable lesion > 1.5 cm as diagnosed by ultrasonography, mri, or ct.
boolean
C0029925 (UMLS CUI [1])
C0278802 (UMLS CUI [2])
C0449453 (UMLS CUI [3])
C0221198 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0041618 (UMLS CUI [5])
C0024485 (UMLS CUI [6])
C0040405 (UMLS CUI [7])
C0278802 (UMLS CUI [2])
C0449453 (UMLS CUI [3])
C0221198 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0041618 (UMLS CUI [5])
C0024485 (UMLS CUI [6])
C0040405 (UMLS CUI [7])
Renal function
Item
3. subject must have good kidney function.
boolean
C0232804 (UMLS CUI [1])
Informed Consent
Item
4. subject must provide written informed consent prior to enrollment.
boolean
C0021430 (UMLS CUI [1])
Condition Present
Item
subjects must be excluded if any of the following conditions are present:
boolean
C0348080 (UMLS CUI [1,1])
C0150312 (UMLS CUI [1,2])
C0150312 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
1. subject is pregnant or breastfeeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Study Subject Participation Status | Investigational New Drugs
Item
2. subject is simultaneously participating in another investigational drug study.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0013230 (UMLS CUI [2])
Clinical Study Follow-up Previous Completed
Item
3. subject has completed the follow-up phase of any previous study less than 30 days prior to enrollment in this study.
boolean
C3274571 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
C0205156 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
Radionuclide Imaging Receive Unable
Item
4. subject is unable to tolerate conditions for radionuclide imaging.
boolean
C0034606 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
C1514756 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
Radiopharmaceutical Interferes with Assessment Technetium 99m Ec20 folate peptide
Item
5. subject has been administered another radiopharmaceutical that would interfere with the assessment of technetium tc 99m ec20.
boolean
C0182638 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C1516048 (UMLS CUI [1,3])
C4042715 (UMLS CUI [1,4])
C0521102 (UMLS CUI [1,2])
C1516048 (UMLS CUI [1,3])
C4042715 (UMLS CUI [1,4])